Sarepta Therapeutics’ (SRPT) Sell Rating Reaffirmed at HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They currently have a $75.00 target price on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential downside of 29.81% from the stock’s current price.

Several other equities research analysts have also commented on the company. StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Evercore ISI reduced their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft initiated coverage on Sarepta Therapeutics in a research report on Tuesday, February 11th. They set a “hold” rating and a $136.00 price objective on the stock. Guggenheim boosted their price objective on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, Piper Sandler decreased their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Sarepta Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $176.77.

Sarepta Therapeutics Stock Down 0.1 %

Shares of SRPT stock opened at $106.86 on Thursday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a 12 month low of $101.15 and a 12 month high of $173.25. The stock has a market cap of $10.21 billion, a P/E ratio of 85.49 and a beta of 0.75. The company has a 50 day simple moving average of $116.47 and a two-hundred day simple moving average of $122.90.

Insider Transactions at Sarepta Therapeutics

In other news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares in the company, valued at approximately $738,234. The trade was a 21.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares in the company, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Sarepta Therapeutics by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock worth $1,104,701,000 after acquiring an additional 117,904 shares during the last quarter. Capital International Investors raised its position in Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock worth $1,057,482,000 after purchasing an additional 2,437,855 shares during the period. Janus Henderson Group PLC lifted its stake in Sarepta Therapeutics by 14.2% in the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after purchasing an additional 543,143 shares during the last quarter. Farallon Capital Management LLC boosted its position in shares of Sarepta Therapeutics by 11.1% during the fourth quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company’s stock valued at $348,368,000 after buying an additional 285,100 shares during the period. Finally, Wellington Management Group LLP grew its stake in shares of Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after buying an additional 665,087 shares during the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.